A tripodal Schiff base ligand, 2,4,6-Tris(4-carboxybenzimino)-1,3,5-triazine (MT) and its trinuclear Dy(III), Er(III), and Gd(III) complexes were synthesized. These were characterized using UV-visible, IR, ¹H, and ¹³C NMR spectroscopies, elemental analysis, and molar conductivity measurements. The spectral studies indicate that the ligand is hexadentate and coordinates to the Ln(III) ions through the oxygen atoms of the carboxylic group. The trinuclear complexes were characterized as being bridged by carboxylate anions to the Dy(III), Er(III), and Gd(III) salen centers and displaying a coordination number of six. Biological studies revealed that MT is more active against the test micro-organisms relative to the trinuclear complexes. Acute toxicity studies revealed that MT is safe and has a wide range of effective doses (ED₅₀). In vivo antimalarial studies indicate that MT could serve as an effective antimalarial agent since it has parasitemia inhibition of 84.02% at 50 mg/kg and 65.81% at 25 mg/kg, close to the value (87.22%) of the standard drug—Artesunate. Molecular docking simulation studies on the compounds against SARS-CoV-2 (6Y84) and E. coli DNA gyrase (5MMN) revealed effective binding interactions through multiple bonding modes. The binding energy calculated for Er(III)MT-6Y84 and Er(III)MT-5MMN complexes showed active molecules with the ability to inhibit SARS-CoV-2 and E. coli DNA gyrase.

This study was aimed at determining the therapeutic value of fresh Musa paradisiaca L. (MP) stem juice as a potential treatment for epileptic convulsions using a pentylenetetrazole (PTZ)-induced seizure model in rats. Six groups of albino rats (n = 4) were involved in the study. Group I was treated with normal saline (p.o), while group II was untreated and group III received diazepam (4 mg/kg, p.o). Group IV, V and VI received 50, 75 and 100% v/v oral dose of MP stem juice, respectively). The treatment lasted for 10 days, followed by PTZ (85 mg/kg b.w, i.p) administration 60 min later. Lethality test and phytochemical screening were conducted. The rats were closely watched and meticulously monitored for seizure manifestations/episodes with the aid of a stop watch. From the results, the MP stem juice up to 100% (v/v) was safe in mice and numerous bioactive compounds were found with phenols being the most abundant (9.46 ± 0.03 mg/g), followed by alkaloids (5.54 ± 0.98 mg/g) and flavonoids (4.27 ± 1.23 mg/g). For the seizure manifestation, three intermittent seizures (episodes 1, 2 and 3) were observed and the stem juice (75 and 100% v/v) significantly (p < 0.05) increased the latency periods of episode 1 tonic and clonic seizures. The stem juice at 50% (v/v) delayed the onset of episode 2 seizures for over 10 minutes more than the untreated group. The groups that received 75 and 100% (v/v) of the stem juice did not experience seizures during the episode 2 as seen in episode 1. The standard and the test groups did not experience seizure during the episode 3. The findings of this study have demonstrated that the fresh MP stem juice could prevent convulsions by increasing the latencies and decreasing relatively the durations of seizures in PTZ-challenged rats. This study, however, provides the pharmacological evidence for the folk claim behind the use of Musa paradisiaca stem juice to manage epileptic convulsions or seizure disorders.

I believe the authors have tried their best in reporting the work, but they still need to do more justice to the discussion because it is not exhaustive enough. Furthermore, they ought to back up their findings with evidences from previous studies. I...

This study was aimed at determining the therapeutic value of fresh _Musa paradisiaca_ L. (MP) stem juice as a potential treatment for epileptic convulsions using a pentylenetetrazole (PTZ)-induced seizure model in rats. Six groups of albino rats (n = 4) were involved in the study. Group I was treated with normal saline (p.o), while group II was untreated and group III received diazepam (4 mg/kg, p.o). Group IV, V, and VI received 50, 75, and 100% v/v oral doses of MP stem juice, respectively). The treatment lasted for 10 days, followed by PTZ (85 mg/kg b.w, i.p) administration 60 min later. A lethality test and phytochemical screening were conducted. The rats were closely watched and meticulously monitored for seizure manifestations/episodes with the aid of a stopwatch. From the results, the MP stem juice up to 100% (v/v) was safe in mice and numerous bioactive compounds were found with phenols being the most abundant (9.46 ± 0.03 mg/g), followed by alkaloids (5.54 ± 0.98 mg/g) and flavonoids (4.27 ± 1.23 mg/g). For the seizure manifestation, three intermittent seizures (episodes 1, 2, and 3) were observed and the stem juice (75 and 100% v/v) significantly (p < 0.05) increased the latency periods of episode 1 tonic and clonic seizures. The stem juice at 50% (v/v) delayed the onset of episode 2 seizures for over 10 minutes more than the untreated group. The groups that received 75 and 100% (v/v) of the stem juice did not experience seizures during episode 2 as seen in episode 1. The standard and the test groups did not experience seizures during episode 3. The findings of this study have demonstrated that fresh MP stem juice could prevent convulsions by increasing the latencies and decreasing the duration of seizures in PTZ-challenged rats. This study, however, provides the pharmacological evidence for the folk claim behind the use of _Musa paradisiaca_ stem juice to manage epileptic convulsions or seizure disorders.